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Cancer cells are metabolically stressed during tumour progression due to limited
tumour vascularity and resultant nutrient, growth factor and oxygen deﬁciency
that can induce cell death and inhibit tumour growth. We demonstrate that
Rab25, a small GTPase involved in endosomal recycling, that is genomically
ampliﬁed in multiple tumour lineages, is a key regulator of cellular bioenergetics
and autophagy. RAB25 enhanced survival during nutrient stress by preventing
apoptosis and autophagy via binding and activating AKT leading to increased
glucose uptake and improved cellular bioenergetics. Unexpectedly, Rab25
induced the accumulation of glycogen in epithelial cancer cells, a process not
previously identiﬁed. Strikingly, an increase in basal ATP levels combined with
AKT-dependent increases in glucose uptake and glycogen storage allowed main-
tenance of ATP levels during bioenergetic stress. The clinical relevance of these
ﬁndings was validated by the ability of a Rab25-dependent expression proﬁle
enriched for bioenergetics targets to identify patients with a poor prognosis.
Thus, Rab25 is an unexpected regulator of cellular bioenergetics implicated as a
useful biomarker and potential therapeutic target.
INTRODUCTION
Cancer cells characteristically require higher levels of nutrients
and energy metabolism than normal cells, due to increased rates
ofcellproliferation thatdemandsynthesis ofproteins, lipidsand
nucleotides as well as energy in the form of adenosine 50-
triphosphate (ATP; Vander Heiden et al, 2009). However, as
cancers grow and metastasize, they frequently outpace their
vascular supply resulting in both nutrient and oxygen depriva-
tion. ATP, the main cellular energy source, is produced
primarily from two sources, glycolysis and mitochondrial
respiration (Krebs cycle and oxidative phosphorylation), with
oxidative phosphorylation providing the majority of ATP.
Cancer cells, with respect to their normal counterparts,
demonstrate increased glycolytic capacity even in the presence
of adequate oxygen supplies (Moreno-Sa ´nchez et al, 2007)
providing energy as well as increased production of cellular
building blocks such as amino acids and fatty acids (Vander
Heiden et al, 2009).
RAB GTPases comprise the largest subfamily of small
GTPases and play a master role in regulating intercellular
vesicle transport and trafﬁcking of proteins (Agarwal et al,
2009). Numerous studies have implicated aberrations in Rab-
regulated vesicle recycling in the initiation and progression of
multiple cancer lineages (Mosesson et al, 2008). We have
previously shown that RAB25 is a candidate oncogene located
within the 1q22 amplicon in ovarian and breast cancers (Cheng
et al, 2004). Rab25, which is primarily expressed in epithelial
cells (Goldenring et al, 1993), is a member of the Rab11
subfamily with its closest homologues Rab11a and Rab11b
(Agarwal et al, 2009). Functional studies demonstrate that the
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and transportacross polarized epithelialcells aswell asin apical
vesicle recycling (Tzaban et al, 2009).
RAB25 is ampliﬁed and over-expressed in many human
cancers. Increased RAB25 mRNA levels have been reported in
ovarian, prostate cancer, transitional cell carcinoma of the
bladder, invasive breast cancer, liver cancer and Wilms tumour
(Agarwal et al, 2009), suggesting a pathological role of Rab25 in
development or progression of multiple tumour lineages. In
addition, we and others have demonstrated that Rab25 increases
anchorage-independent growth, survival in response to growth
factor deprivation, suppresses apoptosis and increases tumour
development, while down-regulation of Rab25 by RNAi transfec-
tion signiﬁcantly inhibits ovarian cancer growth in vivo (Cheng
et al, 2004; Fan et al, 2006). Recent studies demonstrated that
expression of Rab25 in rat intestine epithelial cells leads to
transformation and cancer development (Lapierre et al, 2011).
Further, Rab25 genomic ampliﬁcation and increased mRNA
expression are both associated with poor prognosis in a subset of
ovarian and breast cancers (Cheng et al, 2004). Together, these
data strongly implicate Rab25 in tumour initiation and aggres-
siveness. However, Rab25 has also been suggested to act as a
tumour suppressor in claudin-low breast cancers and in bowel
epithelium (Chenget al, 2010; Namet al, 2010).Thus, Rab25 may
functionasanoncogeneoratumoursuppressordependingonthe
cellular context and the extracellular environment of the tumour.
Analysis oftranscriptional proﬁleshas emerged asa powerful
toolinelucidatingthemolecularmechanismsbywhichagenetic
aberration contributes to cancer development (Nevins & Potti,
2007). To explore the mechanisms by which Rab25 expression
alters cancer cell function, we identiﬁed a RAB25 transcriptome
in vitro. Importantly, the Rab25 signature is portable from cell
lines allowing interrogation of tumour samples. The transcrip-
tome was highly enriched in genes implicated in cellular
metabolism indicating a novel role of Rab25 in regulating
cellular metabolism that we explore further herein.
RESULTS
The Rab25 transcriptome is enriched in metabolism-
associated genes leading to decreased cellular sensitivity to
nutrient stress
Transcriptional proﬁling revealed a Rab25-dependent gene
expression signature containing 1128 probes representing 908
known genes [Fig S1A–C and Table S1 of Supporting
information, raw data was submitted to Gene ExpressionOmni-
bus (GSE28299)]. Based on GeneOntology Biological Process
Classiﬁcation, metabolism-associated genes constituted the
largest category, with over 47% of the Rab25-dependent gene
expression signature being implicated in cellular metabolism,
including lipid, amino acid and carbohydrate metabolism
(Fig S1D and Table S2 of Supporting information). Based on
this potential novel role for Rab25 in regulating cellular
metabolism and the increased glycolytic dependence of cancer
cells, it was of particular interest to evaluate whether Rab25
alterscell survival during nutrient stress by culturing cells under
glucose (deprivation or by addition of 2-deoxyglucose; 2DG) or
amino acid(EBSS) deprivation conditions. Asgrowth factors are
requiredforefﬁcientuptakeandutilizationofnutrients(Edinger
& Thompson, 2002), growth factor deprivation provides a
potentmimicofdecreasedcellularenergybalanceandincreased
cellular stress.
Expression of RAB25 (to levels present in tumours with
ampliﬁed RAB25) in ovarian cancer A2780 and HEY cells or
IOSE29ht immortalized normal ovarian epithelium cells, all of
which express low endogenous levels of RAB25, signiﬁcantly
decreasedcell death(p<0.01) undergrowth factor andnutrient
deprivation conditions, as measured by DNA fragmentation and
ﬂow cytometry of ﬂuorescent-tagged deoxyuridine triphosphate
nucleotide incorporation (Fig 1A and B). In contrast, decreasing
Rab25 expression with siRNA sensitized cells to nutrient
withdrawal-induced cell death (Fig 1B). To further evaluate
the physiological relevance of these ﬁndings, we examined the
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Figure 1. Rab25 expression alters cells sensitivity to nutrient stress.
A. Rab25expressiondecreasesnutrientwithdrawal(24h)inducedcelldeath inovarian A2780 andIOSE29cellsmeasuredusingtheCelldeath ELISAplusassay
(left);cellswereculturedincompletemedia(containing5%FBS), serumfreemedia(SF),completemediaplus2DG,serumandglucosefree media(SF-glu),or
in amino acid, glucose and SF Earls buffer salt solution (EBSS). (a) p<0.01 versus control and (b) p<0.05 versus pcDNA. (Right) Percentage of apoptotic cells
(sub-G0 population) by flow cytometry in A2780 cells following glucose and serum withdrawal (Glu/SF). (a) p<0.001 versus A2780 pcDNA control and
(b) p<0.05 A2780 Rab25 versus A2780 pcDNA control.
B. Decreasing Rab25 expression increases sensitivityto nutrient stressinducedcell death. Expressionof Rab25 was down-regulatedbysiRNA or shRNA specific
to Rab25.
C. Rab25 regulates autophagy activity in ovarian cancer cells under serum and glucose deprivation conditions. Western blot for the 16kD LC3-II fragment,
indicative of autophagy activity, in A2780 cells after 4 and 6h of serum and glucose withdrawal.
D. Electron microscopic analysis of autophagy in ovarian A2780 cells after 4 and 24h of serum and glucose withdrawal (upper panel, low magnification). High
magnification images of boxed areas with arrowheads depicting autophagic vacuoles (lower panel, inset; N: nucleus). Average number of autophagosomes
per cell was calculated by counting the number of autophagosomes in 16 individual cells from two-independent experiments.
E-H. Expression of Rab25 decreases glucose and serum deprivation induced signalling activation. Protein expression was measured by RPPA or WB analysis.
E. RPPA detection of time-dependent activation of AMPK after nutrient withdrawal.
F. WB analysis of AMPK and acetyl-CoA carboxylase (ACC) phosphorylation in HEY ovarian cancer cells (upper panel). WB of phospho-ACC levels in A2780,
IOSE80ht and SKOV3 ovarian cells after 1h of nutrient withdrawal (lower panel).
G. RPPA detection of phosphorylation of ACC after withdrawal of serum and glucose.
H. Effect of Rab25 down-regulation on AMPK (left panel) and ACC (right panel) phosphorylation. Total cellular protein, isolated from A2780 pcDNA and Rab25
expressing cells 72h post-transfection with either non-target (NT) RNAi or Rab25 specific RNAi, was separated by polyacrylamide gel electrophoresis (PAGE)
followed by WB analysis. (a) p<0.001 versus NT RNAi control and (b) p<0.001, pcDNA versus Rab25.
~
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breast MCF7 cancer cell lines, which express high endogenous
Rab25 levels (Cheng et al, 2005). Stable expression of shRNA
speciﬁc to Rab25 signiﬁcantly reduced the expression of Rab25
protein in these cells (Fig S2 of Supporting information). Similar
to the results obtained from HEY cells, reducing Rab25
expression by shRNA led to increased cell death after nutrient
withdrawal in both OVCAR3 and MCF7 cells (Fig 1B).
Under conditions of reduced nutrient availability most cells
undergo autophagy, degrading cytoplasmic organelles to
provide substrates for energy metabolism (Meijer & Codogno,
2004). To elucidate the contribution of autophagy to Rab25-
mediated resistance to metabolic stress in cancer cells, the
formation of autophagosomes, the ﬁnal step in the autophagy
cascade, was assessed by measuring the levels of the
endogenous autophagosomal marker LC3, microtubule-asso-
ciated protein1 light chain 3, by Western blotting (WB) after 4
and 6h of nutrient withdrawal (Mizushima, 2004). Surprisingly,
LC3-II protein fragment levels were lower in Rab25-expressing
A2780andHEYcellsthanincontrolpcDNA-transfectedcellsafter
serum and glucose withdrawal (Fig 1C), suggesting a change in
autophagic activity. Consistent with the WB data, expression of
Rab25 markedly decreasedautophagosome formation (Fig 1D) in
Rab25-expressing A2780 cells (29 7 autophagosome/cells)
compared to control cells (70 11 autophagosomes/cells) after
both glucose and serum withdrawal for 4h (p<0.00057) as
assayed by electron microscopy (EM), a quantitative and
deﬁnitive method for detection of autophagy (Mizushima,
2004). However, prolonged nutrient withdrawal (24h) was
sufﬁcient toinduce autophagyinRab25-transfected cells tolevels
similar to those in parental cells, indicating that the autophagic
machinery is not compromised by the expression of Rab25 but
rather that autophagy induction is delayed.
The Rab25-mediated reduction in autophagy was noted in
multiple cell lines including human osteosarcoma U2OS cells
(Fig S3A of Supporting information), suggesting the effects of
Rab25 on autophagy are generalizable. Autophagy requires the
coordinate activity of multiple ‘autophagy-related’ proteins
(Atg) including Atg6/Beclin1 that has been implicated in human
breast, ovarian and prostate tumours cancer (Karantza-Wads-
worth et al, 2007). Atg6/Beclin1 heterozygous mutant mice are
tumour-prone implicating autophagy in tumourigenicity (Jin &
White, 2007). However, expression of Atg6/Beclin1 was not
signiﬁcantly changed in response to Rab25 expression (Fig S3B
of Supporting information).
50-AMP-activated protein kinase (AMPK) is a major physio-
logical sensor of intracellular energy levels. An increase in
intracellular AMP/ATP ratio activates AMPK to maintain
cellular energy balance (Kahn et al, 2005). As expected,
following nutrient withdrawal, AMPK phosphorylation
(pAMPK) increased as measured by both reverse phase protein
arrays (RPPA; Fig 1E) and WB analysis (Fig 1F). However, the
increase in pAMPK levels was markedly lower in Rab25-
transfected cells following glucose and growth factor with-
drawal (Fig 1E). AMPK, when activated, also phosphorylates
acetyl CoA carboxylase (ACC) resulting in inhibition of energy-
consuming fatty acid synthesis. AMPK phosphorylation levels
paralleled ACC phosphorylation (pACC), as measured by RPPA
(Fig 1G) and WB (Fig 1F). In keeping with the effect of Rab25 on
AMPK phosphorylation, ACC phosphorylation was markedly
decreased in cells expressing Rab25 (Fig 1F). Furthermore,
Rab25 knockdown using RNAi sensitized cells to nutrient stress
as indicated by increases in both basal- and nutrient depriva-
tion-induced AMPK and ACC phosphorylation (Fig 1H).
Rab25 expression alters ATP levels
How does Rab25 expression reduce bioenergetic stress and
delay the onset of autophagy under nutrient deprived condi-
tions? Unexpectedly, Rab25 expression in cells grown in
complete medium (RPMI1640þ5% FBS) results in a consistent
and statistically signiﬁcant elevation of basal ATP levels
compared to pcDNA-transfected cells (Fig 2A). The effects of
Rab25 on ATP levels are even more striking during nutrient
stress.ExpressionofRab25inA2780orHEYovariancancercells
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Figure 2. Expression of Rab25 regulates cellular ATP and glycogen levels.
A. Expression of Rab25 increases endogenous ATP level in ovarian cancer cells.
 p<0.001 Rab25 versus pcDNA. The mean cellular concentration of ATP per mg of
protein (based on the standard curve generated using a known amount of ATP) is 2.36
 10moles/mg for IOSE29ht pcDNA cells, 6.21
 10moles/mg for IOSE29ht
Rab25 cells, 8.14
 11moles/mg for IOSE80ht pcDNA cells, 1.05
 10moles/mg for IOSE80ht Rab25 cells, 2.85
 10moles/mg for A2780 pcDNA cells,
3.81
 10moles/mg for A2780 Rab25 cells, 7.23
 10moles/mg for HEY pcDNA cells and 9.82
 10moles/mg for HEY Rab25 cells.
B. Rab25 expression increases ATP synthesis and delays fall in total cellular ATP levels after glucose and serum withdrawal, p<0.001 Rab25 versus control
pcDNA.
C. Down-regulation of Rab25 expression decreases ability to maintain ATP after glucose and serum withdrawal (a) p<0.05 SF-Glu versus FBS and (b) p<0.05
versus control.
D. Expression of Rab25 increases total cellular glycogen content while down-regulation of Rab25 expression decreases total cellular glycogen content( mgo f
glycogen/mgprotein).Cellswerecultured incomplete mediafor24hbeforeglycogenmeasurement. (a)p<0.01Rab25versuspcDNA,(b)p<0.05Rab25 RNAi
versus NT RNAi and (c) p<0.05 shRAb25 versus shRNA control.
E. Decrease in cellular glycogen content after glucose and serum withdrawal
 p<0.001 Rab25 versus pcDNA.
F. Effect of GPi (Bay U6571) and oligomycin on ATP production. A2780 pcDNA transfected and Rab25 expressing cells were pretreated with vehicle (control),
30mM of Bay U6571 (GPi) or 25mg/ml of oligomycin for 2h. Cells were then cultured in serum- and glucose free RPMI 1640 in the presence of absence of Bay
U6571 or oligomycin for the indicated times. (a) p<0.01 oligomycin time 0 versus control time 0 and (b) p<0.01 versus time 0 at each treatment group.
G. Effect of Bay U6571 on cellular glycogen (left panel) and ATP (right panel) levels in HEY cells. (a) p<0.01 versus pcDNA control time 0 at 5% FBS and (b)
p<0.01 GPi versus control at each corresponding treatment.
H. Down regulation of Rab25 expression and inhibition of glycogen breakdown by GPi administration increases 2DG induced cell death
 p<0.05 versus shRNA
control.
~
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glucoseandFBS(growthfactordeprivation)overatleast6hand
to a lesser degree over 24h of culture (Fig 2B). Hence, the
elevated ATP level in Rab25-expressing cells likely lowers the
AMP/ATP ratio leading to decreased AMPK activation.
Compatible with a role for Rab25 in maintaining ATP levels
under nutrient stress, down-regulation of Rab25 in cells




withdrawal without activation of autophagy could be due to the
utilization of internal nutrient reserves such as glycogen,
triglycerides or proteins, which can be rapidly metabolized for
energyproduction (Greenbergetal,2006). Cellularglycogenbut
not triglyceride or protein levels (data not shown) were
signiﬁcantlyhigherinRab25-expressingcellsgrownincomplete
medium (Fig 2D). This is striking as glycogen has not been
proposed to represent a major component of energy stores
in epithelial cancer cells. Down-regulation of Rab25 expression
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glycogen levels suggesting a role for Rab25 in controlling cellular
glycogen production or storage. Following nutrient deprivation,
glycogen levels fell rapidly, compatible with conversion to
glucose for ATP synthesis (Fig 2E), suggesting that glycogen may
contribute to the maintenance of cellular energy levels during
metabolic stress in Rab25 expressing cells (Fig 2B).
Glycogen is converted to glucose-1-phosphate by glycogen
phosphorylase (GP) and then to glucose-6-phosphate before
entering the glycolytic pathway to produce ATP (Roach, 2002).
We thus determined the effect of preventing conversion of
glycogen to glucose-1-phosphate, by GP inhibition, on ATP
levels. A2780 ovarian cancer cells expressing Rab25 or pcDNA-
transfected cells were pretreated with 30mM Bay U6571 GP
inhibitor (GPi) or 200ng/ml oligomycin (an ATP synthase
inhibitor) for 4h in complete media before nutrient withdrawal.
Incubation of cells with the GPi in complete media did not
signiﬁcantly alter basal ATP levels (Fig 2F), presumably due to
the high concentration of glucose in the media that can be
utilized as an energy source. Strikingly, the presence of GPi
essentially abrogated the ability of Rab25 to maintain cellular
ATP levels after glucose deprivation (Fig 2F), indicating that the
conversion of endogenous glycogen to glucose-1-phosphate
plays a critical role in the ability of Rab25 to maintain elevated
ATP levels during glucose deprivation. Blocking mitochondrial
ATP production by oligomycin signiﬁcantly decreased cellular
ATP levels under all conditions suggesting that a signiﬁcant
component of the ATP production in Rab25-expressing cells is
through oxidative phosphorylation (Fig 2F). The ability of the
GPi to block glycogenolysis and decrease ATP levels during
glucose deprivation was conﬁrmed in Rab25-expressing HEY
(Fig 2G) and MCF7 cancer cells (Fig S4B of Supporting
information). Thus the elevated glycogen stores induced by
Rab25 appear to maintain ATP levels during the early phase of
metabolic stress. In agreement with the changes in cellular ATP
levels, blocking glycogen catabolism by pretreating cells with
the GPi elevated ACC phosphorylation above control levels in
the absence of the GPi (Fig S4C of Supporting information).
Functionally, addition of the glycolysis inhibitor 2DG induced
cell death in both OVCAR3 and MCF7 cells (Fig 2H).
Importantly, reducing Rab25 expression by shRNA-mediated
knockdown increased cell death induced by low dosage 2DG
(2–10mM). Thus, blocking glycogenolysis and subsequent
glycolysis reduce the ability of Rab25-expressing cells to
maintain survival during early nutrient stress, implicating
utilization of glycogen as an important energy source (Fig 2H).
Rab25 regulates cancer cell bioenergetics through an
AKT-dependent pathway
Glycogen synthase (GS), which converts glucose into glycogen
forstorage,isinhibitedbyphosphorylationatseveralsitesbyGS
kinase-3 (GSK3; Woodgett, 1994). GSK3, in turn, is inhibited by
phosphorylationbyAKTfollowingPI3Kpathwayactivation.We
have previously reported that Rab25 expression is associated
with a concomitant increase in AKT activation through a yet
unexplored mechanism (Cheng et al, 2004). Consistent with our
previous observations, AKT S473 phosphorylation, reﬂecting
AKT activation, was markedly increased in Rab25-expressing
cells leading to increased GSK3 phosphorylation and consequent
decreases in GS phosphorylation in the presence or absence of
serum (Fig 3A). To determine whether the activation of AKT and
subsequent inhibition of GSK3 and consequent activation of GS
play a role in determining intracellular glycogen levels, we
examined the effect of inhibition of PI3K or GSK3 by PI103, a
potentandselectiveinhibitorofclassIPI3K(Raynaudetal,2007)
or GSK3i (SB-216763), respectively, on cellular glycogen levels.
Cells were placed in complete media containing PI103 or GSK3i
for 2h to allow PI103 or GSK3i to enter cells, followed by a
2h incubation in glucose- and foetal bovine serum (FBS)-free
medium to induce a reduction in endogenous glycogen levels.
WB demonstrated the efﬁcacy of PI103 and GSK3i in inhibiting
phosphorylation of AKT and GSK3, as well as decreasing
phospho-GS levels (Fig 3B). The GPi Bay U6571 was included
as a control for the speciﬁcity of effects of PI103 and GSK3i.
Treating A2780 pcDNA-transfected ovarian cancer cells with
GSK3i,thusreleasinginhibitionofGSactivityasaconsequenceof
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Figure 3. Rab25 regulates bioenergetics in ovarian cancer cell through the AKT pathway.
A. Rab25 expression increases phospho but not total AKT and GSK3 levels in A2780 cells leading to decreased phosphorylation of GS (pGS).
B. WB analysisofAKTandGSK3phosphorylationconfirmingtheinhibitoryeffectofPI3Kpathwaysinhibitors PI103,GPiandsynthasekinase 3inhibitor(GSK3i)
in HEY cells.
C. Inhibition of GSK3 activity increases total cellular glycogen levels. pcDNA transfected and Rab25 expressing ovarian cancer cells were cultured in complete
media in the presence of 10mM GSK3i for the indicated times. Total cellular glycogen content was measured and normalized with total protein content.
(a) p<0.001 versus no GSK3i treated pcDNA cells.
D-E. Effect of PI3K inhibitor PI103 on cellular glycogen content and ATP production. Ovarian cancer cells were pretreated with PI103 for at least 2h in complete
media. Cells were then subjected to 2h glucose and FBS withdrawal to deplete endogenous glycogen followed by culturing cells in RPMI-glucose media in
the presence of PI103 for 2h (2h SF). After 2h of nutrient stress, complete media containing PI103 was added to the cells for 30min (5% FBS) for recovery.
A second glucose and FBS withdrawal (15min SF) followed immediately to examine the effect on glycogen and ATP levels. a, p<0.001 5% FBS versus 2h
SF, b, p<0.01 15min SF versus 5% FBS.
D. There is an increase in glycogen content during recovery phase (5% FBS) and a decrease in glycogen when cells are subject to a second nutrient stress
(15min SF).
E. Utilization of glycogen to produce ATP.
F. AdditionofAKTinhibitorMK2206(AKTi)abolishesRab25-dependentglycogenstorage.(a)p<0.05versusshRNAcontroland(b)p<0.01SFþAKTiversusSF.
G. Inhibiting AKT pathway and glucose metabolism decreases cell viability. Cells were pretreated with 10mM of PI103 or AKTi, 100mM LND or 3BrPy for 2h
before switching to SF media in the presence of inhibitors for an addition16h before cell titre blue viability assay.
 p<0.001 shRNA Rab25 versus shRNA
control.
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content to levels observed in Rab25-expressing cells (Fig 3C). In
contrast, GSK3i had minimal effects in Rab25-expressing cells
compatible with GSK3 inhibition as a consequence of Rab25-
inducedAKTactivation(Fig3C).Similarresultswereobservedin
HEY and IOSE80ht cells where GSK3i increased glycogen levels
(p<0.05) in pcDNA-transfected cells, whereas, a signiﬁcant
change in glycogen levels was not observed in Rab25-expressing
cells (Fig 3C). Thus, increased AKT activity with subsequent
inhibition of GSK3 in Rab25-expressing cells likely contributes to
increased GS activity and glycogen accumulation.
PI103 did not alter the modest glycogen accumulation that
occurred in pcDNA-transfected HEY or IOSE80ht cells returned
to nutrient- and FBS-replete media (Fig 3D). In both HEY and
IOSE80ht cells, Rab25 expression markedly increased the
accumulation of glycogen in cells released from starvation
(p<0.01). When cells were subjected to a second nutrient
stress, glycogen levels fell rapidly (Fig 3D) suggesting that the
glycogen stored during the short incubation in glucose- and
serum-replete media provides an immediate source of energy.
The role of the PI3K–AKT pathway in maintaining cellular ATP
levels in Rab25 expressing cells was assessed using PI103. The
ability of Rab25 to induce glycogen accumulation (Fig 3D) and
maintain ATP levels (Fig 3E) under stress was compromised in
the presence of PI103, compatible with Rab25 increasing
glycogen stores and maintaining ATP levels during nutrient
stress through Rab25-mediated PI3K pathway activation (Fig 3D
and E).
These observations were further evaluated in OVCAR3 and
MCF7 cells using shRNA-mediated stable knockdown of Rab25
expression, which decreased basal glycogen levels (Fig 3F and
Fig S5A of Supporting information). The speciﬁc AKT inhibitor
(MK2206) signiﬁcantly decreased glycogen levels further and
indeed overrode the effects of Rab25 shRNA supporting a role
for AKT activation in Rab25-induced glycogen accumulation
(Fig S5A of Supporting information). When cells were cultured
inserum-freeconditions,wherein,AKTactivationbyexogenous
stimulation is absent, cells expressing Rab25 maintained
elevated basal glycogen levels, whereas, Rab25 shRNA induced
a decrease in glycogen levels (Fig 3F). MK2206 markedly
decreased glycogen levels and abrogated the effect of Rab25
shRNA (Fig 3F). Similar results were obtained in T47D cells
treated with Rab25 siRNA or with MK2206 (Fig S5B of
Supporting information).
Culturing OVCAR3 and MCF7 cells in serum-free medium led
to a decrease in cell survival (Fig 3G). Knocking down Rab25
levels augmented the cell death (Fig 3G). Inhibition of PI3K or
AKT activity with PI103 or MK2206, respectively, resulted in
similar levels of cell death regardless of the presence of Rab25
shRNA supporting a Rab25/PI3K/AKT-dependent mechanism
for Rab25-mediated cell survival (Fig 3G). Addition of
lonidamine (LND) or 3-bromopyruvate (3BrPy), two potent
glycolysis inhibitors (Pelicano et al, 2006), also signiﬁcantly
decreasedcellviability supportingthedependence onglucose as
an energy source for cell survival.
Cellular glycogen synthesis depends on intracellular glucose.
Glucose uptake, assessed using tritium-labelled 2DG in cells
maintained in Krebs–Ringers phosphate solution (i.e. growth
factor and glucose depleted environment), was signiﬁcantly
higher in Rab25-expressing cells than in parent cells (Fig 4A).
Similarly down-regulation of Rab25 decreased glucose uptake
(Fig 4B). AKT activation has been demonstrated to increase
glucose uptake (Tong et al, 2009). Indeed, treating Rab25 over-
expressing HEY cells with MK2206 effectively inhibited cellular
glucose uptake regardless of the presence or absence of Rab25
(Fig 4B). Similarly, AKT-speciﬁc siRNA (Fig S5C of Supporting
information)decreasedglucoseuptake,supportingacriticalrole
for AKT in Rab25-induced glucose uptake. MK2206 further
reduced glucose uptake (Fig 4B) in the presence or absence of
Rab25 or AKT siRNA further supporting a role for AKT Rab25
function. Likewise, knockdown of endogenous Rab25 or
inhibiting AKT activity in OVCAR3 and T47D cells using
speciﬁc shRNA or MK2206, respectively, signiﬁcantly reduced
glucose uptake (p<0.001) conﬁrming a role for AKT in
regulation of glucose uptake by Rab25 (Fig 4C).
In rat cardiomyocytes, Rab11, the closest Rab family member
to Rab25 (by sequence homology), colocalizes with glucose
transporter (GLUT) 4-containing vesicles and redistributes to
the plasma membrane with GLUT4 (Watson et al, 2004). We,
therefore, reasoned that Rab25 could contribute to GLUT
trafﬁcking. As GLUT1 is the primary GLUT expressed in ovarian
cancer cells (Rudlowski et al, 2004), we examined the
localization of GLUT1 and Rab25 by immunoﬂuorescence
staining under nutrient stress and nutrient-replete conditions in
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Figure 4. Rab25 increases glucose uptake.
A. Rab25 over-expression increases H
3-labelled 2DG uptake. (a) p<0.001 Rab25 versus pcDNA. Results are mean s.d. of a triplicate in one of representative
experiment.
B. Down-regulation of Rab25 or AKT expression, or inhibition AKT activity by MK2206 decreases glucose uptake in HEY cells (a) p<0.001 versus NT siRNA
control, (b) p<0.05 versus siRab25 and (c) p<0.05 versus siAKT.
C. Effect of down regulation of Rab25 and AKT inhibitor MK2206 (AKTi) on glucose uptake. Cells were either pretreated for 2h with AKTi before assessing
glucose uptake. (a) p<0.05 versus shRNA control and (b) p<0.05 versus shRab25.
D. Rab25 co-localization with GLUT1 in A2780 cells. Immunofluorescent staining of GLUT1 (red) and Rab25 (green). Co-localization of GLUT1 and Rab25
(i.e. yellow) is indicated by arrows. Single scale bar, 10mM.
E-G. Resistanceto2DGinducedcelldeathinRab25cellsismediatedthroughthePI3K/AKTpathway.InhibitionofthePI3K/AKTpathwaywasachievedbyaddition
of 10mM of PI103 or MK2206.
E. AKT inhibition increases sensitivity to 2DG induced cell death.
 p<0.001 versus HEY pcDNA cells.
F. Down-regulation of AKT by siRNA specific to AKT.
G. Or down-regulation of Rab25 by shRNA specific to Rab25 enhances 2DG induced cell death.
 p<0.001 versus RNAi control cells.
~
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Figure 5. Detection of physical association between AKT and Rab25 by protein complementation assay (PCA).
A. Ovarian cancer HEY cells (upper panel) wereco-transfected with AKT-IFPNand Rab25-IFPC or with AKT-IFPC and Rab25-IFPN.Cells become fluorescent due to
an interaction between AKT and Rab25 bringing the two halves of the fluorescent protein into proximity creating a stable complex and restoring fluorescence.
Hela cells stably expressing AKT-IFPN (lower panel) were transfected with Rab25-IFPC or PDK-IFPC as control. A brightfield image corresponding to the
fluorescent image is shown and transfected cells indicated by an arrow.
B. Detection of Rab25 and AKT interaction by immunoprecipitation. Ovarian cells expressing HA-tagged Rab25 were IP with anti-HA antibody. The resultant
complex was separated by gel electrophoresis and detected by WB using anti-AKT antibody.
C. GenerationofRab25deletionmutants.Expressionofthedeletionmutantswasdetectedbyimmunofluorescencestaining(upperpanel)andWB(middlepanel)
using anti-GFP antibody which interacts with YFP. Diagrammatic representation of the structure of the mutants is shown in the lower panel.
D. Rab25 deletion mutants do not alter cellular glycogen and ATP levels. Ovarian cancer cell lysates were collected 24h post transfection. (a) p<0.05 versus
empty vector transfected cells.
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glucose and growth factors, GLUT1 co-localized with Rab25 in a
perinuclear distribution (Fig 4D). Addition of FBS as a source of
growth factors andglucose for 5min resulted inredistribution of
a portion of GLUT1 from a perinuclear location to the
cytoplasmic membrane. Importantly, Rab25 colocalized with
GLUT1 during the translocation process (as indicated by
arrows) suggesting that GLUT1 may represent a Rab25 cargo.
High AKT activity has been reported to render cells more
susceptible to death induced by glucose withdrawal or treating
with a glycolysis inhibitor (Elstrom et al, 2004; Fan et al, 2010;
Kurtoglu et al, 2007). Thus, Rab25 expression, with subsequent
increasesinAKTactivationandglucoseuptake,wouldbeexpected
to increase sensitivity to 2DG-induced cell death. However, as
noted above, Rab25 expression decreased sensitivity of HEY cells
to low doses of 2DG (2–10mM), whereas, high doses of 2DG (20–
40mM) led to similar levels of cell death in parental and Rab25-
transfected HEY cells (Figs 2H and 4E). Decreasing expression of
Rab25 or activity of AKT by siRNA speciﬁc to Rab25 (Figs 2H
and 4F) or MK2206 (Fig 4E), respectively, increased cellular
sensitivity to 2DG-induced cell death. Interestingly, 2DG has been
reported to activate the AKT signalling pathway and protect cancer
cells from death (Zhong et al, 2008, 2009). To further evaluate the
relationship between Rab25 and AKT in the response to 2DG,
we examined AKT activation in OVCAR3 and MCF7 cells. 2DG
induced an increase in AKT phosphorylation in both cell lines in a
dose- and time-dependent manner similar to the results reported
by Zhong and colleagues. Down-regulation of Rab25 levels
reduced AKT activation, compatible with Rab25 regulating AKT
activation (Fig S5D and E of Supporting information). As expected,
culturing OVCAR3 or MCF7 cells in 2DG decreased cell viability,
a process that was augmented by siRNA to Rab25 (Fig 4G).
Importantly, the addition of AKT or PI3K inhibitors further
decreased cellular viability independently of the presence or
absence of Rab25 siRNA compatible with the PI3K/AKT pathway
mediating the effects of Rab25 on cellular viability (Fig 4G).
Interaction of Rab25 with AKT is required for effects of Rab25
on cellular metabolism
A protein complementation-based assay (see Materials and
Methods Section of Supporting information for details),
wherein, reconstitution of ﬂuorescence is dependent of
protein–protein binding bringing two fragments of a GFP-like
molecule into proximity, demonstrated the association of Rab25
with AKT (Fig 5A). Transient transfection of: (1) AKT-IFPN
(intensely ﬂuorescent protein amino-terminal half) and RAB25-
IFPC (intensely ﬂuorescent protein carboxy-terminal half) or
(2) AKT-IFPC and RAB25-IFPN fusion proteins in HEY ovarian
cancer cells resulted in ﬂuorescence indicating association of
AKTandRab25proteininthePCAcomplex(Fig5Aupperpanel,
double transfected cell indicated by arrow). No ﬂuorescent cells
were observed in other control conditions including (AKT-IFPC
and IFPN), (AKT-IFPN and IFPC) as well as (Rab25 IFPC and
ACTN4-IFPN) indicating a speciﬁc binding of Rab25 with AKT
(Fig S6 of Supporting information). We further conﬁrmed the
association of Rab25 with AKT using PCA in AKT-IFPN stably
expressing HeLa cells by transient transfection of a Rab25-IFPC
construct (Fig 5A, lower panel). 3-phosphoinositide-dependent
protein kinase-1 (PDK1), a well-established AKT binding
partner, was included as a positive control. In support of an
interaction between AKT and Rab25, AKT and Rab25 could be
co-immunoprecipitated (IP) in ovarian cancer cells expressing
Rab25 (Fig 5B).
To elucidate the molecular mechanism by which Rab25
interacts with AKT, Rab25 deletion mutants were designed
(Fig 5C). Expression of these deletion mutants was demon-
strated by WB and immunoﬂuorescence staining using anti-GFP
antibody (Fig 5C). Wild-type Rab25-YFP localizes to the
perinuclear region similar to endogenous Rab25 (Fig 5C).
Deletion of 43 amino acids from the C-terminal (Rab25-C-del) of
Rab25, containing the putative geranylgeranyl transferase II
acceptor motif CCISL, results in a diffuse distribution of Rab25
throughout the cytosol, while addition of a CCISL motif
to Rab25-C-del (Rab25 C-del-CC) restores the normal Rab25
perinuclear distribution implicating the CCISL motif in Rab25
localization. Deletion of 41 amino acids from the N-terminus of
Rab25 (Rab25 N-del) did not affect localization (Fig 5C).
However, no observable ﬂuorescent complex formed when any
of the mutants were coexpressed with AKT as assayed by the
PCA methodology (data not shown). Thus, a full length Rab25
able to localize to the correct compartment appears necessary to
interact with AKT. Strikingly, transient expression of each of the
mutants that are unable to bind AKT, in contrast to full length
Rab25YFPthatbindsAKT,intoovariancancercellsdidnotalter
cellular glycogen levels or glucose uptake (Fig 5D), supporting
the contention that interaction of Rab25 with AKT is likely
required for the ability of Rab25 to alter glucose uptake and
glycogen storage.
Elevated Rab25 levels in patient samples are associated with
altered cellular bioenergetics
To determine whether the effects of Rab25 on cellular stress
observed in cell lines also occurred in human tumours, we
measured Rab25, total AKT, total AMPK, total ACC, total GS,
pAKT (T308), pAMPK, pACC and pGS protein levels in tumour
lysates from 667 ovarian cancer specimens using RPPA. As
expected, due to ACC being an AMPK target, a positive
correlation (Spearman, p¼1.007161e 32) was observed
between pAMPK and pACC protein levels in ovarian cancer
tissues. This positive correlation also served to validate the
ability to accurately assess pAMPK and pACC in patient
samples. Recapitulating the in vitro data, there was a highly
signiﬁcant inverse correlation between Rab25 levels and
pAMPK (p¼0.00015), pACC (p¼7.93e 12) and pGS
(p¼0.00001) as well as a positive correlation (p¼1.34e 9)
between Rab25 and pAKT in patient samples. We did not
examine the potential correlation between pGSK3 and Rab25 as
available phosphoGSK3 antibodies detect both alpha and beta
forms of GSK3 as well as p90RSK mitigating its utility in RPPA.
Furthermore, we observed a positive correlation (p¼0.032)
betweencellularglycogencontentandexpressionofRab25in31
ovarian patient tumour samples (Fig 6A). Thus, the effects of
Rab25 on cellular metabolism in vitro are recapitulated in
ovarian cancer in the patient.
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dependent transcriptional proﬁle and the effect of Rab25 on
cellular metabolism, we classiﬁed serous ovarian cancers into
Rab25-likeandpcDNA-likebasedontheirexpressionpatternsin
two large-independent publically available datasets (Dressman
et al, 2007 and Tothill et al, 2008, see External Datasets Section
of Supporting information for details) using approaches
described previously (Lee et al, 2006). Using linear discriminant
analysis, leave-one-out cross validation, and cell lines with and
without Rab25 expression as the training set, a Rab25-dependent
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Figure 6. Prediction in clinical samples.
A. Rab25 expression correlates with glycogen levels in patient tumours. Total RNA and total cellular extracts, isolated from 31 ovarian cancer patient
specimens, were subjected to Rab25 gene expression and glycogen content analysis using QPCR and glycogen assay, respectively.
B–C. The Rab25 expression signature identifies patients with a poor prognosis. Ovarian cancer patients were classified as either mirroring the Rab25-associated
gene expression signature (Rab25 signature) or not (non-Rab25 signature) using linear discriminant analysis in BRB tools, in two independent published
ovarian datasets. Progression free survival curves for patients with advanced disease (Stage II to IV) are shown. Univariate analyses were plotted using
Kaplan-Meier method and Coxplots used for multivariate analyses (co-variates included stage, grade, histology and residual disease).
B. Tothill et al, 2008.
C. Dressman et al, 2007.
D. Prediction of breast cancer overall survival in two independent published breast datasets (upper panel) Pawitan et al, 2005 and (lower panel) Chin et al,
2006, based on Rab25-associated gene signature. Breast patient classification was determined by BRB tool class prediction function to identify patientwith
Rab25-associated gene expression signature (Rab25-signature) or without (non-Rab25 signature). All patients from the datasets were included in class
prediction.
E. Proposed model for the mechanism by which Rab25 regulates cellular bioenergetics.
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Supporting information) from the original 1167 probesets
(Fig S1 of Supporting information) – was used to classify
ovarian cancers as Rab25-like in the Tothill et al (Fig 6B) and
Dressman et al (Fig 6C) datasets. Rab25-like cancers were
associated with signiﬁcantly higher rates of relapse (Fig 6B) and
poorer survival (Fig 6C). Furthermore, the Rab25 signature was
an independent prognostic factor in multivariate analysis
(Fig 6B and C), in keeping with a role for Rab25 in modulating
aggressiveness of ovarian cancer. We previously demonstrated
that Rab25 levels alone predict survival only in the subset of
patients with very high and very low levels of Rab25 (Cheng
et al, 2004). In contrast, the Rab25 signature was able to predict
outcomes for all ovarian cancer patients indicating that the
Rab25-dependent signature contains important information
related to ovarian cancer pathophysiology not captured by
Rab25 levels alone. Intriguingly, this signatureis not only highly
portable from cell lines to clinical ovarian tumour samples, but
also proved to be a strong predictor of survival in breast cancer
samples (Fig 6D) usingtwo-independent datasets (Pawitan etal,
2005 and Chin et al, 2006, see External Datasets Section of
Supporting information for details), further supporting the role
of Rab25 in aggressiveness of cancers.
Collectively, our data implicate Rab25 in glucose and
glycogen metabolism. The effects of Rab25 appear to be
mediated, at least in part, through an interaction between
Rab25 and AKT leading to increased glucose uptake, which
combined with AKT-induced inhibition of GSK3 and increase in
GS activities results in higher basal glycogen and elevated ATP
levels. The increased glycogen stores, in turn, provide an
alternative energy source during early nutrient stress reducing
sensitivitytonutrientstressandincreasingcellsurvival(Fig6E).
DISCUSSION
RAB25 is ampliﬁed as part of the 1q22 amplicon in multiple
cancer lineages. In support of an oncogenic function for Rab25,
we have previously demonstrated worsened outcomes for
ovarian and breast cancer patients whose tumours have
markedly elevated Rab25 levels (Cheng et al, 2004). Further,
increased Rab25 levels markedly increased tumour growth in
xenograft models. Similarly, knockdown of Rab25 expression
by RNAi decreases growth of ovarian cancer xenografts
(Fan et al, 2006). Rab25 promotes a5b1 integrin-containing
vesicle trafﬁcking to the membrane of pseudopodal tips,
thereby, facilitating cell invasion (Caswell et al, 2007)
potentially contributing to the aggressiveness of ovarian cancer.
A recent study further demonstrated that overexpression of
Rab25 in rat intestinal cells can lead to microtubule-dependent
transformation in vitro and tumour formation in vivo (Lapierre
et al, 2011). However, other studies have suggested that Rab25
may act as a tumour suppressor under some contexts. Loss of
Rab25 in some triple-negative cell lines (Cheng et al, 2010)
promotes tumourigenicity, and a recent study has reported an
increase in colonic tumour incidence in Rab25-deﬁcient mice
bred into an APCmin/þ genetic background (Nam et al, 2010).
Indeed, we have previously demonstrated that Rab25 is not
sufﬁcient to transform immortalized but non-tumourigenic cells
(Cheng et al, 2004) and similarly, Rab25-knockout mice do not
exhibit signiﬁcant anatomical and pathological abnormalities
(Nam et al, 2010). Consequently, Rab25 may not play a role in
tumour initiation either as a primary oncogene or tumour
suppressor gene, but rather may function as a regulator of
tumour progression in already transformed cells. Thus, the
effects of Rab25 appear to be context-dependent. Rab25 may
exert different effects dependent on the intrinsic expression
patterns in different cell lineages, the presence of different
underlying genomic aberrations, the levels of speciﬁc Rab25
molecular partners, the cargoes being transported in Rab25-
containing vesicles or the response of cells to activation of the
signal transduction pathways controlled by Rab25. Context-
dependent effects on tumour initiation and progression are not
without precedence with both autophagy (Eisenberg-Lerner &
Kimchi, 2009) and TGF beta (Chaudhury & Howe, 2009)
demonstrating tumour inhibiting and promoting activity in
different circumstances. In the present study, we manipulated
Rab25 levels with a combination of enforced expression and
knockdown to elucidate the mechanisms underlying Rab25
function. We identiﬁed a Rab25-associated gene signature using
A2780 ovarian cancer cells in vitro. The Rab25 transcriptome
was capable of identifying ovarian cancer patients with a poor
prognosis with high conﬁdence. Importantly, we observed a
novel role of Rab25 in cellular survival and, in particular, in
regulating cellular metabolism.
Increased glucose consumption is a characteristic of malig-
nant cells. However, early studies noted in vivo that the amount
of glucose uptake in tumours was too high to be utilized solely
through glycolysis (Gullino et al, 1967). Our current data show
thatincreasedRab25expressiondecreasessensitivitytonutrient
stress. Rab25-expressing cells demonstrated an unexpected and
unprecedented increaseincellularglycogenstores. Theelevated
glycogen content in cells with high Rab25 levels is recapitulated
in vivo in patient tumour samples. Glycogen stores have not
previously been proposed as a viable energy source that could
contribute to the ability of epithelial cancer cells to withstand
nutrient stress. Indeed other than clear cell tumours where
glycogen stores are prominent, the ability to store and utilize
glycogen as an energy source has not been implicated in
epithelial tumourigenesis and represents a novel observation in




been associated with poor patient survival (Rudlowski et al,
2004). Strikingly, Rab25 colocalizes with GLUT1 suggesting a
potential role for Rab25 in regulating translocation of GLUT1 to
the membrane thus enhancing glucose uptake. Rab25-mediated
activation of AKT may further enhance glucose uptake. The
increased glucose uptake under nutrient-rich conditions in
Rab25-expressing cells is associated with elevated glycogen
stores, the mobilization of which is sufﬁcient to explain, at least
in part, the maintenance of ATP levels during acute bioenergetic
stress.
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of Rab25 increased AKT activity (Cheng et al, 2004), which led
to increased GSK3 phosphorylation, and subsequent inhibition
of GSK3 activity as demonstrated by decreased GS phosphor-
ylation. Together, this cascade provides an additional mechan-
ism by which Rab25 could increase glycogen synthesis resulting
in glycogen accumulation. Indeed, inhibition of PI3K decreased
the ability to Rab25 to induce glycogen accumulation and
inhibition of GSK3 recapitulated the ability of Rab25 to increase
glycogen storage.
A full length functional Rab25 including the C-terminal
geranylgeranylated motif is required to regulate cancer cell
bioenergetics, at least as compared to either N- or C-terminal
deletion mutants. Newly synthesized Rab proteins must be
geranylgeranylated at C-terminal cysteine residues prior to
anchoring to cellular membranes (Pereira-leal & Seabra, 2000).
In agreement with this requirement, deletion of the C-terminus
of Rab25 (Rab25-C-del) including the putative geranylgerany-
lated motif (CCISL) led to mislocalization of Rab25. Addition of
the CCISL motif to the C-terminal truncation mutant was
sufﬁcient to restore normal Rab25 localization. Deletion of the
N-terminus of Rab25 did not disturb subcellular localization
compatible with the CCISL motif playing a key role in Rab25
localization. However, none of the Rab25 mutants retained the
ability to interact with AKT, or to increase ATP, glycogen
content and glucose uptake compatible with these processes
being dependent on AKT activation. It is likely that the deletion
mutants of Rab25 caused a change in availability of important
functional motifs. For instance, the Rab25-N-del mutant lacks
several functional domains, including RabSF1, RabSF2 and
RabF1, the structural b-sheet and a-helix as well as 2-conserved
G box (GDP/GTP-binding motif elements) that are implicated in
GTP and downstream effector binding (Colicelli, 2004; Itzen &
Goody, 2011; Pereira-leal & Seabra, 2000). Likewise, the
deletion of the C-terminus of Rab25 deletes domains that
interact with the Rab escort protein and Rab GDP-dissociation
inhibitor (Itzen & Goody, 2011; Pereira-leal & Seabra, 2000).
Additional ﬁne mapping may further elucidate the functional
domains of Rab25 required for the interaction of Rab25 with
AKT and functional effects of Rab25. Overall, the coordinate
effects of Rab25 mutation on AKT binding and ATP levels,
glycogen content and glucose uptake suggests that the ability of
Rab25 to bind and regulate AKT plays a critical role in the ability
of Rab25 to regulate cellular bioenergetics, a contention
supported by the PI3K, AKT and GSK3 inhibitor studies. In
particular, it is worth noting that the addition of PI103 or
MK2206 abolished the ability of Rab25 to increase cellular
viability supporting the dependence of Rab25 activity on a
functional PI3K/AKT pathway.
It has been reported that cells with high level of AKT activity
aremore sensitivetoglucosewithdrawal orglycolysisinhibition
induced cell death induced (Elstrom et al, 2004; Fan et al, 2010;
Kurtoglu et al, 2007). Inhibiting glycolysis by 2DG has been
demonstrated to promote nutrient stress-induced cell death and
to enhance the therapeutic efﬁcacy of chemotherapeutic drugs
(Simons et al, 2009). Interestingly, we have observed a decrease
sensitivity of Rab25 expressing cells to low doses of 2DG
(2–10mM) despite elevated AKT activity in these cells. Hence, it
is possible that under the submaximal dose of 2DG (10mM),
Rab25mayaltermetabolismthroughpathwaysparalleltoAktto
inﬂuence the outcome of cellular responses. Further, the
discrepancy may also due to the nature of different cells or
systems used in these studies. In addition, other studies have
suggested that inhibition of glycolysis is not sufﬁcient to explain
the actions of 2DG on cell survival (Ralser et al, 2008). Further,
2DG has been shown to activate AKT and prevent cell death
(Zhong et al, 2008; Zhong et al, 2009). Indeed, lung cancer cells
with low levels of AKT activity were more susceptible to 2DG-
induced cell death (Wangpaichitr et al, 2008). In the present
study, we observed an increase in AKT activation in Rab25-
expressing cells after 2DG administration, and inhibition of AKT
by MK2206 increased cell death in response to 2DG, implicating
AKT in preventing 2DG-induced cell death. AKT has been
suggested to protect cells from 2DG-induced cell death by
negatively regulating AMPK activity (Hahn-Windgassen et al,
2005; Memmott & Dennis, 2009; Priebe et al, 2011). Compatible
with this observation, pAMPK and pACC are decreased in the
presence of Rab25. Activation of mitochondrial-bound hexoki-
nase (Gottlob et al, 2001), or by inhibiting N-linked glycosyla-
tion under normoxia, independent from glycolytic inhibition
(Kurtoglu et al, 2007) have also been proposed as alternative
mechanisms by which AKT protects cells from 2DG-induced
death. Together, these studies suggest that a complex
intracellular response governs the outcome of 2DG cytotoxicity.
It is noteworthy that expression of Rab25 delays induction of
autophagy, which can function as an alternative form of non-
apoptotic cell death under conditions of nutrient deprivation.
TheabilityofRab25 toincrease basal ATPlevelsand tomaintain
ATP levels under early glucose- and serum-deprived conditions
likely plays a major role in preventing the induction of
autophagy. Defects in autophagy have been associated with
increased tumourigenesis (Degenhardt et al, 2006; Liang et al,
1999). Metabolic stress can drive tumour cells with both defects
in autophagy and apoptosis into necrotic cell death (Degenhardt
et al, 2006). Diverting cells to necrotic cell death induces
inﬂammatory cell inﬁltration and cytokine signalling (Proskur-
yakov et al, 2003), which by analogy with the wound healing
process, may facilitate cell proliferation and angiogenesis
favouring tumour growth (de Visser et al, 2006). In addition,
defects in autophagy may allow accumulation of chromosomal
instabilityand genomic mutation, as demonstrated by the higher
rates of gene ampliﬁcation and DNA damage observed in renal
(Mathewetal,2007)andmammaryepithelialcellsinresponseto
metabolic stress when both apoptosis and autophagy were
suppressed (Karantza-Wadsworth et al, 2007). However,
following prolonged bioenergetic stress, ATP levels decrease
in Rab25-expressing cells, AMPK becomes activated and cells
eventually enter autophagy. Thus, Rab25 improves cellular
bioenergetics sufﬁciently to delay the decrease in intracellular
energy levels that induce entry into autophagy.
In conclusion, high levels of Rab25 appear to confer a
functional advantage to cancer cells allowing cellular survival
under acute nutrient stress conditions. In addition, a signiﬁcant
proportion of ovarian and breast cancers display a Rab25-
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involved in cellular metabolism, that predicts a poor outcome.
Together, these data indicate that Rab25 induces resistance of
cancer cells to nutrient stress, contributing to increased aggres-
siveness and poorer survival of patients with ovarian and breast
cancerwithhighlevels ofRab25,andidentiﬁes Rab25as wellasits
functional consequences as potential therapeutic targets in
tumours that express high levels of Rab25.
MATERIALS AND METHODS
Patient samples and cell culture
All patient samples and information were collected under IRB approved
(LAB01-144) and HIPPA compliant protocols in MD Anderson Cancer
Center. All patient samples contained greater than 80% tumour on
histology. HEY, A2780 and SKOV3 ovarian cancer cells were maintained
in RPMI 1640 containing 5% FBS. Immortalized ovarian surface
epithelial cells IOSE29ht and IOSE80ht were maintained in MCDB105/
M199 (50:50) containing 5% FBS as described previously (Cheng et al,
2004). ON-TARGET plus siRNAs specific to Rab25 and AKT were
purchased from Dharmacon Inc. (Lafayette, CO). Rab25 shRNA was
purchased from Origene (Rockville, MD).
Detection of autophagy
Autophagic vacuoles were detected by fluorescence microscopy
labelled with LC3-GFP constructs. Fluorescent images were captured
by fluorescence microscopy (Nikon Eclipse TE 2000-E, Germany) and
analysed using the program IPLab (Scanalytic Inc). EM analysis of
autophagy was carried out in High Resolution Electron Microscopy
Facility at the MD Anderson Cancer Center core.
Detection of glucose uptake, cellular ATP levels, cellular
glucose, glycogen and protein assays
Glucose uptake was measured by incubating cells with 2-H
3-
deoxyglucose. Cellular ATP level was determined using an ATP
Bioluminescence Assay Kit CLS II (Roche Applied Science, Indianapolis,
IN) and normalized to cellular protein levels. Total cellular protein
content was assessed using a BCA assay. Glucose and glycogen levels
were assessed using glucose assay kit (Cat # K606-100) and glycogen
assay kit (K646-100), respectively, obtained from BioVision Inc
(Mountain View, CA) according to the manufacturer’s protocol.
Cell death assays
Apoptotic cells were measured using paraformaldehyde fixed cells
with an APO-DIRECT kit (Phoenix Flow Systems) with flow cytometry
or the Cell Death Detection ELISA
PLUS (Roche Applied Science)
according to the manufacturer protocol. Cell viability was detected
using CellTiter-Blue
1 Cell Viability Assay (Promega, Madison, WI).
Protein expression profiling
WB analysis and reverse phase protein lysate array (RPPA) were carried
as described previously (Cheng et al, 2004; Cheng et al, 2005).
Statistical analysis
Experiment results obtained were statistically evaluated by ANOVA or
Student’s t-test. Differences were considered significant for two-sided
p<0.05 or as designated. We estimated the survival probabilities
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The paper explained
PROBLEM:
Despite progress in molecular medicine, cancer remains one of
the leading causes of death. This is due to a failure to diagnose
diseaseat an early curablestageas wellas to the lackof effective
therapeutic approaches. Alterations in the RAB small GTPases
and the vesicle recycling processes they control contribute to
multiple human diseases including cancer. RAB25, located in the
1q22 amplicon prevalent in many cancers, contributes to the
aggressiveness of breast and ovarian and likely other cancer
lineages. However, the molecular mechanisms underlying the
effects of Rab25 on cancer pathophysiology remain unclear.
RESULTS:
To explore the mechanisms by which Rab25 alters cancer cell
behaviour,weidentifiedaRAB25transcriptome.Importantly,the
Rab25 signature is transferrable allowing interrogation of
tumour samples and identification of patients with a poor
prognosis. The Rab25 transcriptome is highly enriched in genes
involved in cellular metabolism and survival. Indeed, Rab25
potently increases cancer cell survival under nutrient stress via
increased AKT activation and subsequent glucose uptake,
glycogen storage and maintenance of cellular bioenergetics. The
data implicate an unexpected Rab25-induced increase in
glycogen stores providing an energy source used during cell
stress as a novel mechanism by which Rab25 could contribute to
increased tumour aggressiveness and worsened patient out-
comes.
IMPACT:
Given the importance of Rab GTPases in regulating critical
cellular functions, it is not surprising that altered expression or
mutation of Rab proteins and their interacting partners are
associated with human disease. Rab25 and its binding partners
are dysregulated in a number of tumour lineages. Functional
studies demonstrate an impact of Rab25 on cell growth,
proliferation, apoptosis, migration and invasion and in vivo
tumourigenicity in mouse models, as well as an association with
clinical outcomes. An understanding of the role of Rab25 in
tumourigenesis will hasten the evolution of Rab25, its inter-
actingpartnersanddownstreamtargetsasnovelbiomarkersand
therapeutic targets.
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the log-rank test. Statistical analysis was performed by GraphPad
Prism V.4 (San Diego, CA) or SPSS 16.0 (Chicago, IL).
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